Literature DB >> 26942085

Oncolytic immunotherapy: The new clinical outbreak.

Jean-François Fonteneau1, Carole Achard1, Cécile Zaupa2, Johann Foloppe2, Philippe Erbs2.   

Abstract

Year:  2015        PMID: 26942085      PMCID: PMC4760340          DOI: 10.1080/2162402X.2015.1066961

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


× No keyword cloud information.
  12 in total

1.  Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Authors:  Evanthia Galanis; Pamela J Atherton; Matthew J Maurer; Keith L Knutson; Sean C Dowdy; William A Cliby; Paul Haluska; Harry J Long; Ann Oberg; Ileana Aderca; Matthew S Block; Jamie Bakkum-Gamez; Mark J Federspiel; Stephen J Russell; Kimberly R Kalli; Gary Keeney; Kah Whye Peng; Lynn C Hartmann
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

Review 2.  The future of immune checkpoint therapy.

Authors:  Padmanee Sharma; James P Allison
Journal:  Science       Date:  2015-04-03       Impact factor: 47.728

3.  Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Authors:  Carolina S Ilkow; Monique Marguerie; Cory Batenchuk; Justin Mayer; Daniela Ben Neriah; Sophie Cousineau; Theresa Falls; Victoria A Jennings; Meaghan Boileau; David Bellamy; Donald Bastin; Christiano Tanese de Souza; Almohanad Alkayyal; Jiqing Zhang; Fabrice Le Boeuf; Rozanne Arulanandam; Lawton Stubbert; Padma Sampath; Steve H Thorne; Piriya Paramanthan; Avijit Chatterjee; Robert M Strieter; Marie Burdick; Christina L Addison; David F Stojdl; Harold L Atkins; Rebecca C Auer; Jean-Simon Diallo; Brian D Lichty; John C Bell
Journal:  Nat Med       Date:  2015-04-20       Impact factor: 53.440

4.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors:  Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

5.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Authors:  Jeong Heo; Tony Reid; Leyo Ruo; Caroline J Breitbach; Steven Rose; Mark Bloomston; Mong Cho; Ho Yeong Lim; Hyun Cheol Chung; Chang Won Kim; James Burke; Riccardo Lencioni; Theresa Hickman; Anne Moon; Yeon Sook Lee; Mi Kyeong Kim; Manijeh Daneshmand; Kara Dubois; Lara Longpre; Minhtran Ngo; Cliona Rooney; John C Bell; Byung-Geon Rhee; Richard Patt; Tae-Ho Hwang; David H Kirn
Journal:  Nat Med       Date:  2013-02-10       Impact factor: 53.440

6.  Remission of disseminated cancer after systemic oncolytic virotherapy.

Authors:  Stephen J Russell; Mark J Federspiel; Kah-Whye Peng; Caili Tong; David Dingli; William G Morice; Val Lowe; Michael K O'Connor; Robert A Kyle; Nelson Leung; Francis K Buadi; S Vincent Rajkumar; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri
Journal:  Mayo Clin Proc       Date:  2014-05-14       Impact factor: 7.616

Review 7.  Oncolytic virotherapy.

Authors:  Stephen J Russell; Kah-Whye Peng; John C Bell
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

8.  Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.

Authors:  J S Carew; C M Espitia; W Zhao; K R Kelly; M Coffey; J W Freeman; S T Nawrocki
Journal:  Cell Death Dis       Date:  2013-07-18       Impact factor: 8.469

9.  Antitumor Virotherapy by Attenuated Measles Virus (MV).

Authors:  Jean-Baptiste Guillerme; Marc Gregoire; Frédéric Tangy; Jean-François Fonteneau
Journal:  Biology (Basel)       Date:  2013-03-28

Review 10.  Trial Watch:: Oncolytic viruses for cancer therapy.

Authors:  Jonathan Pol; Norma Bloy; Florine Obrist; Alexander Eggermont; Jérôme Galon; Isabelle Cremer; Philippe Erbs; Jean-Marc Limacher; Xavier Preville; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-06-01       Impact factor: 8.110

View more
  4 in total

1.  TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Authors:  V Cervera-Carrascon; M Siurala; J M Santos; R Havunen; S Tähtinen; P Karell; S Sorsa; A Kanerva; A Hemminki
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

2.  Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells.

Authors:  Carole Achard; Jean-Baptiste Guillerme; Daniela Bruni; Nicolas Boisgerault; Chantal Combredet; Frédéric Tangy; Nolwenn Jouvenet; Marc Grégoire; Jean-François Fonteneau
Journal:  Oncoimmunology       Date:  2016-11-18       Impact factor: 8.110

Review 3.  Targeting Autophagy for Oncolytic Immunotherapy.

Authors:  Lulu Hu; Ke Jiang; Chan Ding; Songshu Meng
Journal:  Biomedicines       Date:  2017-01-11

4.  Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

Authors:  Tiphaine Delaunay; Mathilde Violland; Nicolas Boisgerault; Soizic Dutoit; Virginie Vignard; Christian Münz; Monique Gannage; Brigitte Dréno; Kristine Vaivode; Dace Pjanova; Nathalie Labarrière; Yaohe Wang; E Antonio Chiocca; Fabrice Le Boeuf; John C Bell; Philippe Erbs; Frédéric Tangy; Marc Grégoire; Jean-François Fonteneau
Journal:  Oncoimmunology       Date:  2017-12-26       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.